Latest Intelligence on Immunology and Inflammation in Ireland

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Elan/Biogen Idec: Tysabri sees further safety success

Elan and Biogen Idec can breathe a little easier having announced the second round of positive results about the safety of their multiple sclerosis drug Tysabri. These results, which come less than a year after the voluntary withdrawal of the drug from the US market following the death of two patients from a fatal brain disorder, suggest a promising future could still be possible for Tysabri.

Published By Datamonitor
18 Oct 2005
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001

« | 1 | » »|

No help is available.